 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
2 News |  |
- laprituximab emtansine (IMGN289) / ImmunoGen
Enrollment change, Trial termination, Trial primary completion date: A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors (clinicaltrials.gov) - May 7, 2015
P1, N=20, Terminated, Sponsor: ImmunoGen, Inc.
N=86 --> 20 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Apr 2015
- ||| laprituximab emtansine (IMGN289) / ImmunoGen
New P1 trial: A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors (clinicaltrials.gov) - Oct 14, 2013
P1, N=86, Recruiting, Sponsor: ImmunoGen, Inc.